Amsterdam - Delayed Quote EUR

BenevolentAI S.A. (BAI.AS)

0.3640

-0.0080

(-2.15%)

At close: January 10 at 5:18:11 PM GMT+1

We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 24 days ago

BAIVF
BenevolentAI restructures; Lilly preps $15B buyback program

The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

BioPharma Dive last month

LLY

BAI.AS
-2.15%
ABBV
BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission

LONDON, December 11, 2024--Regulatory News: BenevolentAI ("the Company"), a pioneer in integrating artificial intelligence with biopharmaceutical development, today unveils a major strategic overhaul to return the Company to its founding TechBio mission. These changes mark a return to the Company’s foundational strengths, refocusing efforts on core technologies and innovation to better develop transformative drug discovery and development solutions. In parallel, and to support this, the Company

Business Wire last month

BAIVF
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman

LONDON, October 17, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery and development, today announces the appointment of Kenneth (Ken) Mulvany as Executive Chairman. Dr. Joerg Moeller is stepping down as Chief Executive Officer with immediate effect.

Business Wire 2 months ago

BAIVF
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024

LONDON, October 10, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology Officer, will hold a presentation titled "Building Trust and Explainability in using AI in Drug Discovery" at BioTechX Europe in Basel on 10 October 2024 at 11:45 AM CET. The presentation will discuss how explainable artificial intelligence can increase transparency in drug dis

Business Wire 3 months ago

BAIVF
BenevolentAI: using artificial intelligence to speed up drug discovery

British artificial intelligence company BenevolentAI recently signed an exclusive license agreement for a series of novel clinical stage drug candidates with Johnson & Johnson. Their potential was evaluated using the company’s unique AI technology, which, if the compounds prove successful, could hail a significant breakthrough in the way drugs are developed. Abi Millar spoke to the company to find out more.

Pharmaceutical Technology 3 months ago

BAI.AS
-2.15%
BenevolentAI First Half 2024 Earnings: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)

BenevolentAI ( AMS:BAI ) First Half 2024 Results Key Financial Results Net loss: UK£24.8m (loss narrowed by 32% from 1H...

Simply Wall St. 3 months ago

BAIVF
BenevolentAI Interim Results for the Six Months Ended 30 June 2024

LONDON, September 19, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or "the Company" or "the Group") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2024.

Business Wire 3 months ago

BAIVF
BenevolentAI Notice of Interim Results

LONDON, September 06, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months ended 30 June 2024, on Thursday 19 September 2024.

Business Wire 4 months ago

BAIVF
BenevolentAI S.A.'s (AMS:BAI) market cap up €43m last week, benefiting both individual investors who own 28% as well as insiders

Key Insights The considerable ownership by individual investors in BenevolentAI indicates that they collectively have a...

Simply Wall St. 4 months ago

BAIVF
Will BenevolentAI (AMS:BAI) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

BAIVF
BenevolentAI: Appointment of Adviser

LONDON, July 04, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company’s Financial and Capital Markets Adviser, with immediate effect.

Business Wire 6 months ago

BAIVF
BenevolentAI: Leadership Team Change

LONDON, July 03, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors.

Business Wire 6 months ago

BAIVF
BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

LONDON, June 25, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI.

Business Wire 6 months ago

BAIVF
BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit

LONDON, June 19, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming Morgan Stanley 3rd Annual Life Sciences AI Summit, 26-27 June 2024, in New York, US.

Business Wire 6 months ago

BAIVF
BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference

LONDON, June 04, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, 11-13 June 2024 in Miami, US.

Business Wire 7 months ago

BAIVF
BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future

With the business potentially at an important milestone, we thought we'd take a closer look at BenevolentAI S.A.'s...

Simply Wall St. 7 months ago

BAIVF
AstraZeneca selects new heart failure target with BenevolentAI

The target was discovered leveraging the AI-driven drug discovery platform of BenevolentAI and validated by AstraZeneca.

Pharmaceutical Technology 7 months ago

AZN

BAI.AS
-2.15%
BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

LONDON, May 15, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI.

Business Wire 7 months ago

BAIVF
BenevolentAI: Result of Annual General Meeting

LONDON, May 02, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The voting results will be made available shortly on the Company’s website (www.benevolent.com/investors/general-meetings/), where the full documentation regarding the AGM can also be found.

Business Wire 8 months ago

BAIVF

Performance Overview

Return	BAI.AS	AEX-Index
YTD	-9.23%	+2.12%
1-Year	-66.61%	+14.50%
3-Year	-96.17%	+12.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BenevolentAI S.A. (BAI.AS)

We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate

BenevolentAI restructures; Lilly preps $15B buyback program

BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission

BenevolentAI Appoints Kenneth Mulvany as Executive Chairman

BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024

BenevolentAI: using artificial intelligence to speed up drug discovery

BenevolentAI First Half 2024 Earnings: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)

BenevolentAI Interim Results for the Six Months Ended 30 June 2024

BenevolentAI Notice of Interim Results

BenevolentAI S.A.'s (AMS:BAI) market cap up €43m last week, benefiting both individual investors who own 28% as well as insiders

Will BenevolentAI (AMS:BAI) Spend Its Cash Wisely?

BenevolentAI: Appointment of Adviser

BenevolentAI: Leadership Team Change

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit

BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference

BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future

AstraZeneca selects new heart failure target with BenevolentAI

BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

BenevolentAI: Result of Annual General Meeting

Performance Overview